Revvity Develops High-Throughput T-SPOT.TB Platform for Large Clinical Labs — Revvity, Inc.

Event summary

Revvity is developing the T-SPOT™ A201, a high-throughput automated platform for latent tuberculosis (TB) testing in large clinical labs.
The platform can process up to 384 samples per instrument in an 8-hour shift with minimal hands-on time.
Targeted launch is set for the second half of 2027, subject to regulatory approval.
Revvity's Euroimmun business will showcase automation solutions at the ADLM 2026 conference.

The big picture

Revvity’s T-SPOT A201 platform addresses the growing demand for scalable TB testing solutions, driven by immigration screening and public health programs. The development aligns with broader industry trends toward automation in clinical diagnostics, positioning Revvity to capture a larger share of the high-volume lab market. With 2025 revenue of $2.9 billion, Revvity is leveraging its existing automation portfolio to expand its diagnostic capabilities.

What we're watching

Regulatory Approval: The pace at which Revvity secures regulatory approval for the T-SPOT A201 will determine its market readiness by late 2027.
Market Adoption: How clinical labs integrate this high-throughput platform into existing workflows could impact Revvity's competitive positioning in TB diagnostics.
Competitive Dynamics: Whether Revvity can sustain its lead in automation solutions for infectious disease testing amid potential rival advancements.